Odanacatib (INN;[1] codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis.

[2] It is an inhibitor of cathepsin K,[3] an enzyme involved in bone resorption.

The phase III clinical trial for this medicine was stopped early after a review showed it was highly effective and had a good safety profile.

[4] In 2016, Merck discontinued development of odanacatib and announced it would not seek regulatory approval after analysis discovered an increased risk of stroke.

This drug article relating to the musculoskeletal system is a stub.